Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PCNA | P12004 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309409 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AEPHX2PCNA | |
| SCHEMBL12858792 | 0.89 | MEN1 (0.42) | MEN1KMT2AEPHX2CA12CA1 | |
| SCHEMBL26234016 | 0.87 | EPHX2 (0.42) | MEN1KMT2AEPHX2CA12CA1 | |
| SCHEMBL25885419 | 0.85 | CASP2 (0.50) | SMN1; SMN2MEN1KMT2AEPHX2PCNA | |
| SCHEMBL17447168 | 0.84 | MEN1 (0.41) | SMN1; SMN2MEN1KMT2ACA12CA1 | |
| SCHEMBL30180923 | 0.84 | EPHX2 (0.50) | SMN1; SMN2EPHX2TSHR | |
| SCHEMBL16358264 | 0.84 | CA2 (0.39) | SMN1; SMN2MEN1KMT2ACA12CA1 | |
| SCHEMBL22515375 | 0.84 | NAAA (0.50) | SMN1; SMN2MEN1KMT2AEPHX2PCNA | |
| SCHEMBL12733548 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AEPHX2PCNA | |
| SCHEMBL16329534 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AEPHX2PCNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | SMN1; SMN2 3449/4885MEN1 674/4885KMT2A 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.